Advances in CAR-T Therapy in Lymphoma - N.Grover - 20260302

Chimeric antigen receptor T‑cell (CAR‑T) therapy has rapidly evolved from a treatment for relapsed/refractory large B‑cell lymphoma to an expanding platform with new targets, earlier‑line indications, and novel manufacturing approaches. This clinically focused Grand Rounds will review the most recent developments in CAR‑T therapy for lymphoma, including updates on efficacy, toxicity management, and emerging real-world data. The session will also highlight ongoing research in CD30-directedCAR‑T therapy and discuss its potential role across CD30‑expressing lymphomas. A patient who recently underwent CAR‑T treatment will share their journey to provide a firsthand perspective on decision-making, expectations, and survivorship.

Natalie Grover MD

2/3/2026 8:45:00 PM